Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science

Coverage, in order

1. 17d ago
   
   MedCity News indie study

   Lycia Lands a $317M IPO for Inflammation Drugs Based on Nobel Prize-Winning Science

   Lycia Therapeutics’ protein-degrading drugs are based on the research of Carolyn Bertozzi, a Stanford chemistry professor and Nobel laureate. Lycia’s lead drug candidate is in development for food allergy, where it could compete against the blockbuster Roche drug Xolair.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.